News Sentiment

BMY sentiment intelligence

Bristol-Myers Squibb Company news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 56 Balanced news tone 39 relevant articles
Exchange NYSE United States
Sector Healthcare Market context
Industry Drug Manufacturers - General Read-through group
Latest close 54.00 Week of 19 Jun 2026
Weighted tone 56/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

77/100 classification confidence.

Company focus 39

directly relevant articles

Source quality 4

high-authority source matches

Trend context Trend inactive

-5.5% over one week, -9.2% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Positive

3 Reasons to Buy Bristol Myers Squibb Stock

Market Reaction

Price moving ahead of tone

64/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 77/100 classification
One-week reaction -5.5% Price reacting lower
Trend fit Trend inactive -9.2% over four weeks
Fair value 9.9% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 13
Neutral 23
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 39
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Market source 8
simplywall.st 6
MarketWatch 2
Investing.com 2
marketscreener.com 2
StockStory 2
The Motley Fool 1
Bristol Myers Squibb 1

Event Lens

What the news is about

Classified themes
Market update 18
Earnings 9
Capital return 7
Analyst action 2
Deals and strategy 1
Guidance 1
Regulatory and legal 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 39
MarketWatch Direct company coverage

Bristol Myers Squibb Co. stock outperforms competitors on strong trading day

Bristol Myers Squibb Co. (BMY) shares rose 1.30% to $54.70 on Monday, outperforming its competitors during a mixed trading session. This gain broke a four-day losing streak for the stock. The Dow Jones Industrial Average saw a slight increase, while the S&P 500 Index experienced

Tone
Positive 72/100
Event
Market update
Published
22 Jun 2026 16:38
Source
MarketWatch
Bristol Myers Squibb Direct company coverage

Harnessing the Potential of Anti-Cancer Modalities

Bristol Myers Squibb (BMS) is developing new anti-cancer modalities, including antibody-drug conjugates (ADCs), protein degraders, and CAR T cell therapy, to combat aggressive and treatment-resistant cancers. ADCs use targeted drug delivery by combining antibodies with potent pay

Tone
Neutral 50/100
Event
Market update
Published
22 Jun 2026 10:07
Source
Bristol Myers Squibb
Kavout Direct company coverage

Why is Barclays Bullish on Bristol-Myers Squibb (BMY) Now

Barclays recently upgraded Bristol-Myers Squibb (BMY) to a "Strong-Buy" due to renewed confidence in its late-stage pipeline, strategic initiatives, and a stronger 2026 outlook. Despite patent cliffs for key drugs, BMY's R&D, new product launches, acquisitions, and a 4.0% dividen

Tone
Positive 75/100
Event
Deals and strategy
Published
21 Jun 2026 00:07
Source
Kavout
AD HOC NEWS Direct company coverage

Bristol Myers Squibb Stock - Weekly review and sector comparison after a quiet news week

Bristol Myers Squibb (BMY) stock had a quiet week with limited company-specific headlines, closing at $54.10 on June 18, 2026. The stock's performance was stable in comparison to its healthcare peers and the broader US equity market. Analysts maintain a "Hold" rating with an aver

Tone
Neutral 50/100
Event
Analyst action
Published
19 Jun 2026 20:07
Source
AD HOC NEWS
Investing.com Direct company coverage

Bristol Myers Squibb declares $0.63 quarterly dividend

Bristol Myers Squibb (NYSE:BMY) has declared a quarterly dividend of $0.63 per share, payable on August 3, 2026, to stockholders of record on July 2, 2026. This extends their 56-year streak of consecutive dividend payments, with the stock currently yielding 4.51%. The company als

Tone
Positive 72/100
Event
Capital return
Published
18 Jun 2026 17:37
Source
Investing.com
MarketWatch Direct company coverage

Bristol Myers Squibb Co. stock outperforms competitors despite losses on the day

Bristol Myers Squibb Co. (BMY) shares decreased by 2.32% to $54.00, marking the fourth consecutive day of losses. Despite this, the stock underperformed the broader market, as the S&P 500 Index (SPX) rose by 1.08% and the Dow Jones Industrial Average (DJIA) increased by 0.14% on

Tone
Negative 38/100
Event
Market update
Published
18 Jun 2026 16:38
Source
MarketWatch
Business Wire Direct company coverage

Bristol Myers Squibb to Report Results for Second Quarter 2026 on July 30, 2026

Bristol Myers Squibb (NYSE: BMY) announced it will release its second quarter 2026 financial results on Thursday, July 30, 2026. Company executives will host a conference call at 8:15 a.m. ET to discuss the results, with a live audio webcast available for investors and the public

Tone
Neutral 50/100
Event
Earnings
Published
18 Jun 2026 11:00
Source
Business Wire
GuruFocus Direct company coverage

Bristol-Myers Squibb (BMY) Maintains Quarterly Dividend at $0.63 per Share

Bristol-Myers Squibb (BMY) announced a quarterly dividend of $0.63 per share, maintaining its previous payout, which results in a forward yield of 4.56%. The company, a significant player in the biopharmaceutical sector with a market cap of $112.89 billion, shows strong profitabi

Tone
Neutral 50/100
Event
Earnings
Published
18 Jun 2026 06:16
Source
GuruFocus
Clinical Trials Arena Direct company coverage

EHA26: BMS touts positive multiple myeloma data for two pipeline candidates

Bristol Myers Squibb (BMS) presented positive clinical trial data for two of its multiple myeloma (MM) pipeline candidates, mezigdomide and arlocabtagene autoleucel (arlo-cel), at EHA 2026. The Phase III SUCCESSOR-2 trial showed mezigdomide extended progression-free survival sign

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 03:37
Source
Clinical Trials Arena
Simply Wall Street Direct company coverage

Bristol Myers Squibb (BMY) Reports Strong Myeloma Trial Results And Early CAR T Progress

Bristol Myers Squibb (BMY) announced positive late-stage clinical trial results for two multiple myeloma treatments, mezigdomide and their CAR T-cell therapy, arlocabtagene autoleucel. These results, presented at the European Hematology Association Congress 2026, suggest strong p

Tone
Positive 71/100
Event
Earnings
Published
18 Jun 2026 01:26
Source
Simply Wall Street
Market source Direct company coverage

Bristol Myers Squibb (BMY) Unveils Myeloma Trial Win And New Gulf Leadership

Bristol Myers Squibb (BMY) announced positive Phase III trial results for a multiple myeloma treatment and encouraging early data for a new CAR T-cell therapy, bolstering its hematology pipeline. The company also appointed a new General Manager for the Gulf region, signaling a st

Tone
Positive 73/100
Event
Earnings
Published
17 Jun 2026 22:15
Source
Market source
Market source Direct company coverage

Bristol Myers Squibb (BMY) Stock Moves -1.14%: What You Should Know

Bristol Myers Squibb (BMY) stock recently decreased by 1.14%, closing at $55.28, which slightly outperformed the S&P 500's larger daily loss. The company's upcoming earnings are projected to show a 10.27% increase in EPS, although revenue is expected to decline by 4.89%. Analysts

Tone
Neutral 50/100
Event
Earnings
Published
17 Jun 2026 22:07
Source
Market source
marketscreener.com Direct company coverage

Bristol Myers Squibb Declares Quarterly Dividend, Payable on August 3, 2026

Bristol Myers Squibb has declared a quarterly dividend of $0.63 per share, as announced by its Board of Directors. This dividend is scheduled to be paid on August 3, 2026, to stockholders who are on record by the close of business on July 2, 2026. The company's stock is listed on

Tone
Positive 63/100
Event
Capital return
Published
17 Jun 2026 21:07
Source
marketscreener.com
marketscreener.com Direct company coverage

Bristol-Myers Squibb Keeps Quarterly Dividend at $0.63 per Share, Payable August 3 to shareholders of Record July 2

Bristol-Myers Squibb (NYSE: BMY) has declared a quarterly dividend of $0.63 per share. This dividend will be payable on August 3 to shareholders of record as of July 2. The pharmaceutical company continues to maintain its steady dividend payouts.

Tone
Neutral 50/100
Event
Capital return
Published
17 Jun 2026 20:39
Source
marketscreener.com
TradingView Direct company coverage

Bristol Myers Squibb Announces Dividend

Bristol Myers Squibb (BMY) has announced a dividend. This news is a brief update from Reuters, indicating a financial action by the company.

Tone
Positive 68/100
Event
Capital return
Published
17 Jun 2026 20:16
Source
TradingView